Zobrazeno 1 - 10
of 15
pro vyhledávání: '"M. A. Pessi"'
Autor:
Roberto Labianca, Giordano D. Beretta, Basem Kildani, Laura Milesi, Federica Merlin, Stefania Mosconi, M. Adelaide Pessi, Tiziana Prochilo, Antonello Quadri, Gemma Gatta, Filippo de Braud, Jacques Wils
Publikováno v:
Critical Reviews in Oncology/Hematology. 74:106-133
Colon cancer is one of the leading tumours in the world and it is considered among the big killers, together with lung, prostate and breast cancer. In the recent years very important advances occurred in the field of treatment of this frequent diseas
Autor:
Anna Maria Baldelli, Salvatore Siena, R. R. Silva, F. Ferraù, Daniele Santini, M. A. Pessi, Sandro Barni, Vincenzo Catalano, Giuseppe Tonini, Nicola Battelli, Stefania Antognoli, Francesco Graziano, Roberto Labianca, D. Mari, D. Priolo, Stefano Cascinu, Paolo Giordani, A. Zaniboni, Cristian Massacesi, Roberto Maisano, Silvia Rota
Publikováno v:
Annals of Oncology. 13:716-720
Background: To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination (TOMOX) as first-line chemotherapy for patients with advanced colorectal cancer. Materials and methods: Previously untreated patients with metastatic col
Autor:
A. Guglielmi, Giovanni Luca Frassineti, Daniele Turci, R. Labianca, Enrico Cortesi, L. Gallo, M. A. Pessi, F. Grossi, E Recaldin, Alberto Sobrero, P Testore, C. Caroti, Carlo Aschele, A Ravaioli, M. Cirillo
Publikováno v:
British Journal of Cancer
We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer. Biochemical modulation was an essential
Autor:
M. A. Pessi, Gino Luporini, Antonio Ardizzoia, Marina Cazzaniga, G. Ugolini, Sandro Barni, E. Del Ferro, Roberto Labianca, G. Zamparelli, Stefano Cascinu, Marco B. L. Rocchi, M. Ligi, Giuseppina Catalano, G. Ghiandoni
Publikováno v:
Supportive Care in Cancer. 5:314-317
Diarrhea is one of the dose-limiting toxicities for administration of fluorouracil (5FU) in patients with colorectal cancer and can result in severe morbidity and mortality. No well-defined prognostic factors influencing 5FU-associated diarrhea have
Publikováno v:
Journal of Bone Oncology
Osteonecrosis of the Jaw (ONJ) is an adverse event reported especially in patients receiving cancer treatments regimen, bisphosphonates (BPs), and denosumab. We performed an open-label, prospective study in patients treated with zoledronic acid who d
Publikováno v:
Tumori Journal. 86:1-3
Autor:
G. D. Beretta, S. Mosconi, L. Milesi, M. A. Pessi, R. Labianca, V. Valentini, M. Campitelli, G. Mantini, L. L. Gunderson, M. G. Haddock
Publikováno v:
Atlas of Endoanal and Endorectal Ultrasonography ISBN: 9788847021761
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1cfd0d5285e8f57b640c485d67c4c72
https://doi.org/10.1007/978-88-470-2129-7_9
https://doi.org/10.1007/978-88-470-2129-7_9
Publikováno v:
Drugs. 61(12)
Colorectal cancer is still a majorhealth and social problem. However, many important advances in treatment have been made in the last 4 to 5 years, and more optimism is now justified both among clinicians and patients. In surgically resectable diseas
Publikováno v:
Tumori. 86(4)